The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
Open accessAbstract
Individuals with hemizygous germline fumarate hydratase (FH) mutations are predisposed to renal cancer. These tumors predominantly exhibit functional inactivation of the remaining wild-type allele, implicating FH inactivation as a tumor-promoting event. Hypoxia-inducible factors are expressed in many cancers and are increased in clear cell renal carcinomas. Under normoxia, the HIFs are labile due to VHL-dependent proteasomal degradation, but stabilization occurs under hypoxia due to inactivation of HIF prolyl hydroxylase (HPH), which prevents HIF hydroxylation and VHL recognition. We demonstrate that FH inhibition, together with elevated intracellular fumarate, coincides with HIF upregulation. Further, we show that fumarate acts as a competitive inhibitor of HPH. These data delineate a novel fumarate-dependent pathway for regulating HPH activity and HIF protein levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to requiring 2-oxoglutarate as a cosubstrate, the HIF hydroxylases have been reported to be inhibited by citrate, isocitrate, succinate, fumarate, malate, oxaloacetate, and pyruvate (Dalgard et al., 2004; Hewitson et al., 2007; Isaacs et al., 2005; Koivunen et al., 2007a; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2005
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2005
In the citing paper
“Similar to succinate, fumarate contributes to the inactivation of PHD, stabilizing HIF proteins to promote cell survival133”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [133]
In the citing paper
“For example, the HIF1α transcription factor accumulates in SDH and FH mutant tumors, presumably due to inhibition of the EglN prolyl hydroxylases (Dahia et al., 2005; Isaacs et al., 2005; Pollard et al., 2005, 2007; Selak et al., 2005).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Isaacs et al., 2005
In the citing paper
“A similar model of substrate-mediated PHD inhibition has been described (23, 37, 42) in which the loss of fumarate hydratase activity leads to the accumulation of fumarate, which also can inhibit PHD competitively.”
From Loss of the SdhB, but Not the SdhA, Subunit of Complex II Triggers Reactive Oxygen Species-Dependent Hypoxia-Inducible Factor Activation and Tumorigenesis (2008) · cites this paper as [23]
In the citing paper
“PHDs are inactive at low O2 and can be inactivated by the accumulation of TCA metabolites fumarate and succinate, which may occur from mutations in the tumor suppressor genes succinate dehydrogenase subunit B or fumarate hydratase (187, 334, 384).”
From Redox regulation of mitochondrial function (2012) · cites this paper as [187]
In the citing paper
“In addition to affecting the activity of chromatin-associated αKG-dependent dioxygenases, succinate and fumarate accumulation can also inhibit αKG-dependent prolyl hydroxylases, leading to stabilization of HIF-1 and concomitant activation of the HIF/hypoxia transcriptional program (184, 185).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [184]
In the citing paper
“High levels of succinate and fumarate can inhibit PHD2 activity through product-mediated inhibition of PHD function, leading to HIF-1α protein stabilization under normoxic (20% O2) conditions (100, 101).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [100]
In the citing paper
“Subsequent work confirmed that fumarate could inhibit PHD2 (Isaacs et al., 2005)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“elevated levels of succinate or fumarate can inhibit PHD activity [65, 66]”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [65]
In the citing paper
“Both succinate and fumarate are competitive PHD inhibitors, and the massive accumulation of these metabolites in cells lacking SDH or FH activity elicit a hypoxic response even under oxygen-replete condition (Isaacs et al., 2005; Selak et al., 2005).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“Furthermore, both succinate and fumarate aberrantly increase the function of hypoxia inducible factors (HIFs).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Isaacs et al., 2005
In the citing paper
“In the case of D2HGA, about 50% of patients present with D2HGDH mutations, while the remaining half possess mutations in the Krebs cycle enzyme isocitrate dehydrogenase 2 (IDH2), which converts isocitrate to α-KG110.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [110]
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Self-citationThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Self-citationHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Self-citationA conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
(1999) · PubMed · Cited by 2,204
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 3×
“Succinate also upregulates HIF by inhibiting its proline hydroxylation (Selak et al., 2005), but in vitro enzyme kinetic analysis proves it to be a weaker antagonist of 2-OG, a finding in keeping with its reduced potency (relative to fumarate) in causing intracellular HIF accumulation in A549 cells.”
BackgroundInfluential
Flagged first, then by citations
1 of the 63 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–800 of 957
The peptidyl prolyl isomerase, PIN1 induces angiogenesis through direct interaction with HIF-2α
Choi, M., Saeidi, S., Han, H., Kim, S., Kwon, N., Kim, D., Min, S., Choi, B. Y., & Surh, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.015 · Cited by 7
Cellular and Molecular Defenses Against Hypoxia
Frede, S., & Fandrey, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8772-2_2 · Cited by 8
The importance of histology and cytogenetics in decision making for renal cell carcinoma
Garcia, J. G., Picken, M. M., & Flanigan, R. C. (2008) · World Journal of Urology · doi:10.1007/s00345-008-0262-3 · Cited by 7
Metabolomic Studies on Cancer and on Anticancer Drugs by NMR Ex Vivo
Chung, Y., & Griffiths, J. R. (2011) · Encyclopedia of Magnetic Resonance · doi:10.1002/9780470034590.emrstm1093 · Cited by 7
Self-citationSpiller, P. F., Morgan, H. J. N., Navegantes, L. C. C., Machado, B. H., da Silva, M. P., & Moraes, D. J. A. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00967.2024 · Cited by 6
Regulators of Cancer Progression: Succinylation
Gao, J., & Yu, W. (2025) · Cancers · doi:10.3390/cancers17162652 · Cited by 6
Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6
Corner, T. P., Salah, E., Tumber, A., Holt‐Martyn, J. P., Brewitz, L., & Schofield, C. J. (2025) · ChemMedChem · doi:10.1002/cmdc.202500682 · Cited by 6
CDC5L drives FAH expression to promote metabolic reprogramming in melanoma
Gu, Z., Zhang, H., Li, Y., Shen, S., Yin, X., Zhang, W., Cheng, R., Zhang, Y., Zhang, X., Chen, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23107 · Cited by 7
Crooks, D. R., Cawthon, G. M., Fitzsimmons, C. M., Perez, M., Ricketts, C. J., Vocke, C. D., Yang, Y., Middelton, L. A., Nielsen, D., Schmidt, L. S., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad131 · Cited by 6
Self-citationTransglutaminase 2: The Maestro of the Oncogenic Mediators in Renal Cell Carcinoma
Nezir, A. E., Ulukan, B., & Telci, D. (2019) · Medical Sciences · doi:10.3390/medsci7020024 · Cited by 6
Expression of Hypoxia-Inducible Factors in Different Stages of Pancreatic Tumor Progression
Jung, J. H., Sosnowska, D., Weaver, J., Parson, H. K., CASELLINI, C. M., & Vinik, A. I. (2020) · Reports — Medical Cases Images and Videos · doi:10.3390/reports3040030 · Cited by 6
Functional Characterization of FH Mutation c.557G>A Underlies Uterine Leiomyomas
Li, P., Wu, Y., Wu, H., Xiong, Q., Zhao, N., Chen, G., Wu, C., & Han, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031452 · Cited by 6
Metabolism and Oxidative Stress Response Pathways in Kidney Cancer: A Tale of Chance and Necessity
Sourbier, C., Srinivasan, R., & Linehan, W. M. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.220 · Cited by 6
Self-citationHereditary urological cancer syndromes
Jefferson, K. P., & Gillatt, D. A. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0761 · Cited by 6
Genetic insights into the hypoxia-inducible factor (HIF) pathway
Kiriakidis, S., Esteban, M. A., & Maxwell, P. H. (2007) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.12.009 · Cited by 6
Genetic approaches to understand cellular responses to oxygen availability
Ortmann, B. M., & Nathan, J. A. (2021) · FEBS Journal · doi:10.1111/febs.16072 · Cited by 7
Rational Therapy for Renal Cell Carcinoma Based on its Genetic Targets
Messer, J. C., Drabick, J. J., & Kaag, M. G. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_13 · Cited by 6
Lou, S., Ren, L., Xiao, J., Ding, Q., & Zhang, W. (2012) · PubMed · Cited by 6
Viperin: A Multifunctional Protein in Antiviral Immunity and Disease Pathogenesis
Cui, Q., Miao, Y., Li, M., Zheng, H., & Yuan, Y. (2025) · Pathogens · doi:10.3390/pathogens14050510 · Cited by 5
Zheng, X., & Yin, H. R. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10695-y · Cited by 5
A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis
Giordano, A., Stridh, P., Preziosa, P., Pisa, M., Lerma-Martin, C., Sorosina, M., Mascia, E., Santoro, S., Misra, K., Clarelli, F., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-02984-w · Cited by 7
The clinical landscape of HIF2α inhibitors in oncology
Saad, E., Machaalani, M., McDermott, D. F., & Choueiri, T. K. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01145-y · Cited by 4
Identification of hub genes with prognostic values in multiple myeloma by bioinformatics analysis
Yang, J., Wang, F., Zhong, S., & Chen, B. (2021) · Hematology · doi:10.1080/16078454.2021.1943617 · Cited by 5
Liu, Y., Chen, Y., Cheng, J., Yan, J., Xue, C.-Y., Pan, H.-Y., Shen, X.-Y., Zhou, J., Jiang, P., Zhou, Y., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03573 · Cited by 5
Park, M. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512037 · Cited by 4
Behnes, C. L., Schlegel, C., Shoukier, M., Magiera, I., Henschke, F., Schwarz, A., Bremmer, F., & Loertzer, H. (2013) · BMC Urology · doi:10.1186/1471-2490-13-3 · Cited by 5
Molecular Genetics and Cancer Biology
Gonzalgo, M. L., & Meeker, A. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00018-9 · Cited by 5
Hu, Y., Zhu, X., Zhao, R., Wang, J., Song, Y., Nie, G., Tang, H., & Wang, Y. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0363 · Cited by 5
Divatia, M. K., & El‐Zaatari, Z. M. (2020) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_877_19 · Cited by 5
Panarsky, R., Crooks, D. R., Lane, A. N., Yang, Y., Cassel, T., Fan, T. W. ‐., Linehan, W. M., & Moscow, J. A. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00214-9 · Cited by 5
Self-citationLoncaric, D., Rodríguez, L., Debeissat, C., Touya, N., Labat, V., Villacreces, A., Bouzier‐Sore, A., Pasquet, J., de la Grange, P. B., Vlaski‐Lafarge, M., et al. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10111-9 · Cited by 8
Long‐lived mitochondrial (Mit) mutants of Caenorhabditis elegans utilize a novel metabolism
Butler, J. A., Ventura, N., Johnson, T. E., & Rea, S. L. (2010) · The FASEB Journal · doi:10.1096/fj.10.162941 · Cited by 5
The Metabolism of Cell Growth and Proliferation
Finley, L. W. S., & Thompson, C. B. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00013-5 · Cited by 6
Fumarate hydratase deficiency induces chronic myeloid leukemia progression
Li, S., Qiao, C., Yang, L., Hong, M., Fang, Y., Jin, H., Li, J., & Qian, S. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.03.23 · Cited by 5
Durślewicz, J., Wybierała, A. M., Szczepanek, S., Antosik, P., Jaworski, D., & Grzanka, D. (2024) · Cancers · doi:10.3390/cancers16071273 · Cited by 5
Kinetic Analysis of HIF Prolyl Hydroxylases
Koivunen, P., & Myllyharju, J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7665-2_2 · Cited by 5
Kim, J., Jeong, H., Heo, D. S., Keam, B., Moon, K. C., Kwak, C. H., Jang, J., Kim, S., Kim, J., Lee, S., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3466 · Cited by 4
Self-citationGenetics of Renal Cell Carcinoma
Ball, M. W., & Linehan, W. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92309-3_3 · Cited by 5
Self-citationSchrader, K. A., Sharaf, R., Alanee, S. R., & Offit, K. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00012-6 · Cited by 5
Novel Insights into FH-associated Disease are KEAPing the Lid on Oncogenic HIF Signalling
Adam, J., Ratcliffe, P. J., & Pollard, P. J. (2011) · Oncotarget · doi:10.18632/oncotarget.348 · Cited by 5
Self-citationQADEER, A., Ullah, A., Khan, M. Z., Alsharif, K. F., Alzahrani, F. M., Alzahrani, K. J., & Abuderman, A. (2026) · Metabolites · doi:10.3390/metabo16030207 · Cited by 5
Karsikas, S. (2015) · Cited by 4
Kiyama, R., Zhu, Y., & Aoyagi, T. (2013) · InTech eBooks · doi:10.5772/54588 · Cited by 4
Incidental diagnosis of HLRCC following investigation for Asperger Syndrome: actionable and actioned
Duong, B., Savarirayan, R., & Winship, I. (2015) · Familial Cancer · doi:10.1007/s10689-015-9829-5 · Cited by 4
Modeling dioxygenase enzyme kinetics in familial paraganglioma
Peters, J. P., Her, Y. F., & Maher, L. J. (2015) · Biology Open · doi:10.1242/bio.013623 · Cited by 4
Pseudohypoxia, Mitochondrial Mutations, the Warburg Effect, and Cancer.
Sanders, E. (2012) · Cited by 4
Glycolytic Pathway as a Target for Tumor Inhibition
Lu, W., & Huang, P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6615-5_5 · Cited by 4
Global chemical modifications comparison of human plasma proteome from two different age groups
Liu, Y., Pan, X., Zhao, M., & Gao, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-72196-z · Cited by 6
Raimundo, N., Fernández-Mosquera, L., & Yambire, K. F. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3612-0_9 · Cited by 4
Shi, Y. X., Xu, Y., Wang, C., Chen, Y., Ren, X., Kang, Y., & Wang, C. (2023) · Genes · doi:10.3390/genes14030744 · Cited by 4
The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies
Schmidt, L. S., Srinivasan, R., & Linehan, W. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2400-0_1 · Cited by 4
Self-citationHereditäre Nierenzellkarzinome
Hartmann, A., Stöhr, C., & Junker, K. (2010) · Der Pathologe · doi:10.1007/s00292-010-1357-3 · Cited by 4
Stenman, M., Staehler, M. D., Szabados, B. E., Sandström, P., Laurell, A., Lindskog, M., & Harmenberg, U. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1537505 · Cited by 4
Serra, D., Amaro, P., Gonçalo, M., Silva, M., Ferrando, B., Pasini, B., & Figueiredo, A. (2012) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/120347541201600315 · Cited by 4
Tumor Cell Complexity and Metabolic Flexibility in Tumorigenesis and Metastasis
Berridge, M. V., & Herst, P. M. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_2 · Cited by 3
Molecular Pathology of the Genitourinary Tract: Molecular Pathology of Kidney and Testes
Sirintrapun, S. J., & Parwani, A. V. (2009) · Surgical pathology clinics · doi:10.1016/j.path.2008.08.003 · Cited by 3
Skin rash, a kidney mass and a family mystery dating back to World War II
Toon, C. W., Hasovits, C., Paik, J. Y., Field, M., Chou, A. S. Y., Hugh, T. J., Pavlakis, N., & Gill, A. J. (2014) · The Medical Journal of Australia · doi:10.5694/mja13.00230 · Cited by 3
Hereditary leiomyomatosis and renal cell cancer syndrome – case report and review of the literature
Popa, L. G., Lutuc, R., Mihai, M. M., Salem, I. A., Negoita, S. I., Giurcăneanu, C., & Fica, S. V. (2020) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.61.2.29 · Cited by 3
Dierolf, J. G., Hunter, H., Watson, A. J., & Betts, D. H. (2022) · Stem Cells and Development · doi:10.1089/scd.2021.0347 · Cited by 3
Oxidative Stress and Hypoxia in Cancer: Implications for Radiation Therapy
Roy, A., Tubin, S., Dwarakanath, B. S. R., & Gupta, S. (2022) · Springer eBooks · doi:10.1007/978-981-15-9411-3_136 · Cited by 3
Edosuyi, O., Choi, M., Igbe, I., & Oyekan, A. (2022) · Research Results in Pharmacology · doi:10.3897/rrpharmacology.8.79765 · Cited by 3
Hong, S., Yum, S., Ha, N., & Jung, Y. (2010) · Analytical Biochemistry · doi:10.1016/j.ab.2010.08.013 · Cited by 3
Self-citationPaddenberg, R., Howold, N., Hoger, C., Janßen, H., Grau, V., & Kummer, W. (2009) · Cell Biochemistry and Function · doi:10.1002/cbf.1608 · Cited by 3
Cheng, B.-Q., Segersvärd, R., Permert, J., & Wang, F. (2010) · European Surgical Research · doi:10.1159/000319876 · Cited by 3
HIF-1-regulated glucose metabolism in the control of apoptosis signaling
Fulda, S. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.3.303 · Cited by 3
Molecular Genetics of Renal Cell Carcinoma
Fukawa, T., Shannon, N. B., Huang, D., Tan, J. Y., Yao, X., Rozen, S., Tan, P., & Teh, B. T. (2017) · Springer eBooks · doi:10.1007/978-4-431-55531-5_3 · Cited by 3
Hereditary Renal Cell Carcinoma
Baba, M., Schmidt, L. S., & Linehan, W. M. (2017) · Springer eBooks · doi:10.1007/978-4-431-55531-5_2 · Cited by 4
Self-citationHIF inhibition: Current strategies and clinical challenges
Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3
“Accordingly, accumulation of tricarboxylic-acid-cycle intermediates such as succinate and fumarate, most often due to SDH or FH loss-of-function, competitively inhibits PHDs and stabilizes HIF-α during normoxia [169,170].”
Arellano-Villavicencio, J. E., Vázquez-Jiménez, A., Vázquez-Jiménez, A., Oropeza-Valdéz, J., Padrón-Manrique, C., Prado-Garcı́a, H., & Tovar, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010894 · Cited by 3
PHD1-dependent hydroxylation of RepoMan (CDCA2) on P604 modulates the control of mitotic progression
Druker, J., Jiang, H., Shakir, D., Child, F., Álvarez, V., Platani, M., Corno, A., Alabert, C., Saurin, A. T., Swedlow, J. R., et al. (2026) · eLife · doi:10.7554/elife.108131.3 · Cited by 2
Joshi, A., Dai, L., Maisiak, M., Lee, S., Lopez, E. F., Ito, T., & Neckers, L. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0194 · Cited by 3
Self-citationIdentification of High-Performing Blood Metabolite Biomarkers of Lung Cancer in a Chinese Population
Chen, Z., Zhang, L., Mao, K., Li, J., Zhou, Y., Zheng, J., LeVatte, M., Wishart, D. S., Huang, Y., Huang, Y., et al. (2026) · Phenomics · doi:10.1007/s43657-024-00206-5 · Cited by 2
Multiple Cutaneous and Uterine Leiomyomatosis
Makino, T. (2013) · InTech eBooks · doi:10.5772/53601 · Cited by 2
Yum, S., Choi, J., Hong, S., Park, M. H., Lee, J., Ha, N., & Jung, Y. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.033 · Cited by 2
Self-citationPathology of Renal Cell Carcinomas
Zhou, M. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-149-3_4 · Cited by 2
Dai, K., Jiang, W., Chen, S., Luo, S., Ding, S., & Wang, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.932996 · Cited by 2
A big picture of the mitochondria-mediated signals: From mitochondria to organism
Acar, N. V., & Özgül, R. K. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.08.032 · Cited by 2
Damage-associated molecular patterns as metabolic regulators of innate immunity
Ryan, T. A. J., Zanoni, I., & Gioia, M. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-15447-8.00007-6 · Cited by 2
Kurtz, A., Wenger, R. H., & Eckardt, K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381462-3.00092-6 · Cited by 2
Cancer Hypoxia and the Tumour Microenvironment as Effectors of Cancer Metabolism
Armitage, E. G., Kotze, H. L., & Williams, K. J. (2014) · SpringerBriefs in systems biology · doi:10.1007/978-1-4939-0615-4_2 · Cited by 2
Molecular Pathogenesis of Renal Cell Carcinoma: A Review
Gomy, I., & Silva, W. A. (2012) · InTech eBooks · doi:10.5772/27950 · Cited by 2
Regulation of endogenous erythropoietin production
Mole, D. R., & Ratcliffe, P. J. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8698-6_2 · Cited by 2
Self-citationPark, H. (2008) · Toxicological Research · doi:10.5487/tr.2008.24.2.101 · Cited by 2
Management of Atypical Renal Cell Carcinomas
Liaw, B. C.-H., Mehrazin, R., Baker, C., Sfakianos, J. P., & Tsao, C. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0501-1 · Cited by 2
Papillary Renal Cell Carcinoma
Srinivasan, R., & Hammerich, K. H. (2018) · Springer eBooks · doi:10.1007/978-3-319-96989-3_5 · Cited by 2
Genetics and Tumor Microenvironment of Renal Cell Carcinoma
Khaleel, S. S., Ricketts, C. J., Linehan, W. M., Ball, M. W., Manley, B. J., Turajlic, S., Brugarolas, J., & Hakimi, A. A. (2022) · Société Internationale d’Urologie Journal · doi:10.48083/blpv3411 · Cited by 2
Self-citationMitochondrial Mutations in Cancer Progression: Causative, Bystanders, or Modifiers of Tumorigenesis?
Kurelac, I., Vidone, M., Girolimetti, G., Calabrese, C., & Gasparre, G. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_10 · Cited by 2
Mitochondrial-to-Nuclear Communications in Cancer
Dakubo, G. D. (2010) · Springer eBooks · doi:10.1007/978-3-642-11416-8_4 · Cited by 2
Genetic Alterations in Pheochromocytoma and Paraganglioma
Welander, J. (2015) · Linköping University medical dissertations · doi:10.3384/diss.diva-114806 · Cited by 2
MOLECULAR AND CLINICAL CHARACTERISTICS OF TRICARBOXYLIC ACID CYCLE-ASSOCIATED TUMORS
Lehtonen, H. J. (2008) · Työväentutkimus Vuosikirja · Cited by 2
Renal tumors: The good, the bad, and the ugly
Flanigan, R. C. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01838.x · Cited by 2
Biological Aspects in Renal Cell Carcinoma
Médina, V., Aparicio, G., & Aparicio, L. M. A. (2012) · InTech eBooks · doi:10.5772/27010 · Cited by 2
The Role Of Fumarase (FH) In Tumorigenesis
Lehtonen, R. (2006) · Työväentutkimus Vuosikirja · Cited by 2
Clinical Trials for Specific Renal Cancer Subtypes—The Time Will Come!
Rupp, N. J., Montironi, R., Mischo, A., & Moch, H. (2017) · European Urology Supplements · doi:10.1016/j.eursup.2017.08.007 · Cited by 2
Targeting HIF-1α Function in Cancer through the Chaperone Action of NQO1Preprint
SALIDO, E. C., Timson, D. J., Betancor-Fernández, I., Palomino‐Morales, R., & Pey, A. L. (2020) · Preprints.org · doi:10.20944/preprints202003.0285.v1 · Cited by 2
Iwert, C., Stein, J., Appelt, C., Vogt, K., Rainer, R. J., Tummler, K., Mühle, K., Stanko, K., Schumann, J., Uebe, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.20.440500 · Cited by 1
Depletion of FH, an essential TCA cycle enzyme, drives proliferation in a two-step modelPreprint
Solaimuthu, B., Lichtenstein, M., Hayashi, A., Khatib, A., Plaschkes, I., Nevo, Y., Tanna, M., Lavi, S., Pines, O., & Shaul, Y. D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.16.496410 · Cited by 2
Engineered probiotics limit CNS autoimmunity by stabilizing HIF-1α in dendritic cellsPreprint
Sanmarco, L., Rone, J. M., Polonio, C., Giovannoni, F., Lahore, G. F., Ferrara, K., Gutiérrez-Vázquez, C., Li, N., Sokolovska, A., Plasencia, A., et al. (2023) · bioRxiv · doi:10.1101/2023.03.17.532101
Identification of the binding proteins of organic acid metabolites by matrix thermal shift assay
Li, K., Ye, Y., Zhang, X., Zhou, J., Li, Y.-N., & Ye, M. (2024) · Chinese Journal of Chromatography · doi:10.3724/sp.j.1123.2023.07002 · Cited by 1
Metadata
- Authors
- Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., Ratcliffe, P. J., Linehan, W. M., & Neckers, L.
- Affiliations
- National Institutes of Health (US)
- Pusan National University (KR)
- University of Oxford (GB)
- National Cancer Institute (US)
- St George's Hospital (GB)
- Corresponding author
- Neckers, Len
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-08
- Volume
- 8
- Issue
- 2
- Pages
- 143-153
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2059747280
- Semantic Scholar
- 6906ef0c1fe45571640c3c7a6b3c9c2d9a979a64
- Cited by
- 958
- References
- 63
- Citations by year
- 2026: 26 · 2025: 30 · 2024: 30 · 2023: 36 · 2022: 45 · 2021: 37 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 40 · 2016: 44 · 2015: 64 · 2014: 54 · 2013: 60 · 2012: 64
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- fumarate hydratase, hypoxia-inducible factor, fumarate, HIF prolyl hydroxylase, competitive inhibition, clear cell renal cell carcinoma, biallelic loss, cancer susceptibility, hypoxia
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Adult, Alleles, Carcinoma, Renal Cell, DNA-Binding Proteins, Female, Fumarate Hydratase, Fumarates, Humans, Ketoglutaric Acids, Kidney Neoplasms, Male, Middle Aged, Nuclear Proteins, Procollagen-Proline Dioxygenase, Syndrome, Transcription Factors, Up-Regulation, Gene Expression Regulation, Neoplastic, Leiomyomatosis, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
